Pharmaceutical Executive-01-01-2008

Pricing, safety, comparative effectiveness, patents, and biosimilars top 2008's policy agenda

We asked seven industry experts to talk about today's best (and worst) pharma icons

Pharma defends itself against claims made in charity's report on drug access for the world's poor

Pharm Exec asks experts to predict what 2008 has up its sleeve for the industry--from the top line to the bottom line, from R&D to M&As, from Congress to the courts.

A new report says FDA is desperately behind on science. At last, a critique we can actually do something about. But will we?

The departure of Wyeth's legendary CEO prompts a reflection on true leadership-and cooking

Welcome to the new employer's market for reps. The Hay Group's annual survey reports how, as the primary sales force contracts, so too does its pay.

When it comes to clinical teams, the question of whether or not to outsource brings some untraditional answers

Pharma companies would do well to proceed with extreme caution when entering the blogosphere

Novartis' Paul Herrling talks about how Big Pharma can learn from nonprofit R&D and collaborate to get an edge on the drug safety problem.